BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol 2021;75:659-89. [PMID: 34166721 DOI: 10.1016/j.jhep.2021.05.025] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Umbro I, Baratta F, Angelico F, Del Ben M. Nonalcoholic Fatty Liver Disease and the Kidney: A Review. Biomedicines 2021;9:1370. [PMID: 34680486 DOI: 10.3390/biomedicines9101370] [Reference Citation Analysis]
2 van Kleef LA, Sonneveld MJ, de Man RA, de Knegt RJ. Poor performance of FIB-4 in elderly individuals at risk for chronic liver disease - implications for the clinical utility of the EASL NIT guideline. J Hepatol 2021:S0168-8278(21)02012-2. [PMID: 34461208 DOI: 10.1016/j.jhep.2021.08.017] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Venkatesh SK, Torbenson MS. Liver fibrosis quantification. Abdom Radiol. [DOI: 10.1007/s00261-021-03396-y] [Reference Citation Analysis]
4 Guerra S, Mocciaro G, Gastaldelli A. "Adipose tissue insulin resistance and lipidome alterations are the characterizing factors of NASH". Eur J Clin Invest 2021;:e13695. [PMID: 34695228 DOI: 10.1111/eci.13695] [Reference Citation Analysis]
5 Rosato V, Ascione A, Nevola R, Fracanzani AL, Piai G, Messina V, Claar E, Coppola C, Fontanella L, Lombardi R, Staiano L, Valente G, Fascione MC, Giorgione C, Mazzocca A, Galiero R, Perillo P, Marrone A, Sasso FC, Adinolfi LE, Rinaldi L. Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. J Viral Hepat 2021. [PMID: 34582610 DOI: 10.1111/jvh.13617] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Huang Y, Gan Q, Lai R, Wang W, Guo S, Sheng Z, Chen L, Guo Q, Cai W, Wang H, Zhao G, Cao Z, Xie Q. Application of Fatty Liver Inhibition of Progression Algorithm and Steatosis, Activity, and Fibrosis Score to Assess the Impact of Non-Alcoholic Fatty Liver on Untreated Chronic Hepatitis B Patients. Front Cell Infect Microbiol 2022;11:733348. [DOI: 10.3389/fcimb.2021.733348] [Reference Citation Analysis]
7 Hsieh M, Kao T, Hsieh T, Kao C, Peng C, Lai H, Chuang P, Kao J. Long-term surveillance of liver histological changes in chronic hepatitis C patients completing pegylated interferon-α plus ribavirin therapy: an observational cohort study. Therapeutic Advances in Chronic Disease 2022;13:204062232110676. [DOI: 10.1177/20406223211067631] [Reference Citation Analysis]
8 Han E, Kim HS. Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2021;45:698-707). Diabetes Metab J 2021;45:972-3. [PMID: 34847647 DOI: 10.4093/dmj.2021.0315] [Reference Citation Analysis]
9 Fujita K, Masaki T. Serum Biomarkers of Liver Fibrosis Staging in the Era of the Concept "Compensated Advanced Chronic Liver Disease". J Clin Med 2021;10:3340. [PMID: 34362121 DOI: 10.3390/jcm10153340] [Reference Citation Analysis]
10 Semmler G, Egger M, Hefner E, Datz C. Letter to Niezen and colleagues. Liver Int 2021;41:2525-6. [PMID: 34392604 DOI: 10.1111/liv.15037] [Reference Citation Analysis]
11 Grgurevic I, Bozin T, Mikus M, Kukla M, O'Beirne J. Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease: From Epidemiology to Diagnostic Approach. Cancers (Basel) 2021;13:5844. [PMID: 34830997 DOI: 10.3390/cancers13225844] [Reference Citation Analysis]
12 Nielsen AS, Askgaard G, Thiele M. Treatment of alcohol use disorder in patients with liver disease. Curr Opin Pharmacol 2022;62:145-51. [PMID: 34999372 DOI: 10.1016/j.coph.2021.11.012] [Reference Citation Analysis]
13 Dobbie LJ, Kassab M, Davison AS, Grace P, Cuthbertson DJ, Hydes TJ. Low Screening Rates Despite a High Prevalence of Significant Liver Fibrosis in People with Diabetes from Primary and Secondary Care. J Clin Med 2021;10:5755. [PMID: 34945051 DOI: 10.3390/jcm10245755] [Reference Citation Analysis]
14 Ciardullo S, Ballabeni C, Trevisan R, Perseghin G. Liver Stiffness, Albuminuria and Chronic Kidney Disease in Patients with NAFLD: A Systematic Review and Meta-Analysis. Biomolecules 2022;12:105. [DOI: 10.3390/biom12010105] [Reference Citation Analysis]
15 Mertens J, De Block C, Spinhoven M, Driessen A, Francque SM, Kwanten WJ. Hepatopathy Associated With Type 1 Diabetes: Distinguishing Non-alcoholic Fatty Liver Disease From Glycogenic Hepatopathy. Front Pharmacol 2021;12:768576. [PMID: 34759828 DOI: 10.3389/fphar.2021.768576] [Reference Citation Analysis]
16 Sanduzzi-Zamparelli M, Mariño Z, Lens S, Sapena V, Iserte G, Pla A, Granel N, Bartres C, Llarch N, Vilana R, Nuñez I, Darnell A, Belmonte E, García-Criado A, Díaz A, Muñoz-Martinez S, Ayuso C, Bianchi L, Fuster-Anglada C, Rimola J, Forner A, Torres F, Bruix J, Forns X, Reig M. Liver cancer risk after HCV cure in patients with advanced liver disease without non-characterized nodules. J Hepatol 2021:S0168-8278(21)02228-5. [PMID: 34856322 DOI: 10.1016/j.jhep.2021.11.023] [Reference Citation Analysis]
17 Sachar Y, Brahmania M, Dhanasekaran R, Congly SE. Screening for Hepatocellular Carcinoma in Patients with Hepatitis B. Viruses 2021;13:1318. [PMID: 34372524 DOI: 10.3390/v13071318] [Reference Citation Analysis]
18 Majumdar A, Tsochatzis EA. Non-invasive tests and advanced chronic liver disease in NAFLD: two steps forward and one step back? Gut 2021:gutjnl-2021-325994. [PMID: 34521766 DOI: 10.1136/gutjnl-2021-325994] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Le MH, Yeo YH, Li X, Li J, Zou B, Wu Y, Ye Q, Huang DQ, Zhao C, Zhang J, Liu C, Chang N, Xing F, Yan S, Hui WZ, Sook Yee NT, Mayumi M, Liu X, Liu C, Rui F, Yang H, Yang Y, Jin R, Le RHX, Xu Y, Le DM, Barnett S, Stave CD, Cheung R, Zhu Q, Nguyen MH. 2019 Global NAFLD Prevalence: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01280-5. [PMID: 34890795 DOI: 10.1016/j.cgh.2021.12.002] [Reference Citation Analysis]
20 Roeb E. Nichtalkoholische Steatohepatitis (NASH) und alkoholische Steatohepatitis (ASH). Drug Res (Stuttg) 2021;71:S16-8. [PMID: 34788881 DOI: 10.1055/a-1606-5858] [Reference Citation Analysis]
21 Le Garf S, Nègre V, Anty R, Gual P. Metabolic Fatty Liver Disease in Children: A Growing Public Health Problem. Biomedicines 2021;9:1915. [PMID: 34944730 DOI: 10.3390/biomedicines9121915] [Reference Citation Analysis]
22 Canivet CM, Smati S, Lannes A, Brisseau J, Judon L, Roch ML, Cariou B, Bellanger W, Guerci B, Boursier J. Awareness of chronic liver diseases, a comparison between diabetologists and general practitioners. Clin Res Hepatol Gastroenterol 2021;:101848. [PMID: 34922062 DOI: 10.1016/j.clinre.2021.101848] [Reference Citation Analysis]
23 Blanco-Grau A, Gabriel-Medina P, Rodriguez-Algarra F, Villena Y, Lopez-Martínez R, Augustín S, Pons M, Cruz LM, Rando-Segura A, Enfedaque B, Riveiro M, Casis E, Ferrer-Costa R, Buti M, Rodriguez-Frias F. Assessing Liver Fibrosis Using the FIB4 Index in the Community Setting. Diagnostics (Basel) 2021;11:2236. [PMID: 34943471 DOI: 10.3390/diagnostics11122236] [Reference Citation Analysis]
24 Liu Y, Liu C, Li J, Kim TH, Enomoto H, Qi X. Risk stratification of decompensation using liver stiffness and platelet counts in compensated advanced chronic liver disease (CHESS2102). J Hepatol 2021:S0168-8278(21)02112-7. [PMID: 34662676 DOI: 10.1016/j.jhep.2021.10.006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
25 Mak AL, Lee J, van Dijk AM, Vali Y, Aithal GP, Schattenberg JM, Anstee QM, Brosnan MJ, Zafarmand MH, Ramsoekh D, Harrison SA, Nieuwdorp M, Bossuyt PM, Holleboom AG. Systematic Review with Meta-Analysis: Diagnostic Accuracy of Pro-C3 for Hepatic Fibrosis in Patients with Non-Alcoholic Fatty Liver Disease. Biomedicines 2021;9:1920. [PMID: 34944736 DOI: 10.3390/biomedicines9121920] [Reference Citation Analysis]
26 Hwang TI, Han AL. Quality of Life in Adults with Metabolic Dysfunction-Associated Fatty Liver Disease. Int J Environ Res Public Health 2021;18:13145. [PMID: 34948754 DOI: 10.3390/ijerph182413145] [Reference Citation Analysis]
27 Liu Y, Tang T, Örmeci N, Huang Y, Wang J, Li X, Li Z, An W, Liu D, Zhang C, Liu C, Liu J, Liu C, Wang G, Mosconi C, Cappelli A, Bruno A, Akçalar S, Çelebioğlu E, Üstüner E, Bilgiç S, Ellik Z, Asiller ÖÖ, Li L, Zhang H, Kang N, Xu D, He R, Wang Y, Bu Y, Gu Y, Ju S, Golfieri R, Qi X. Noncontrast-enhanced MRI-based Noninvasive Score for Portal Hypertension (CHESS1802): An International Multicenter Study. J Clin Transl Hepatol 2021;9:818-27. [PMID: 34966645 DOI: 10.14218/JCTH.2021.00177] [Reference Citation Analysis]
28 Loosen SH, Kostev K, Keitel V, Tacke F, Roderburg C, Luedde T. An elevated FIB-4 score predicts liver cancer development: A longitudinal analysis from 29,999 patients with NAFLD. J Hepatol 2021:S0168-8278(21)02028-6. [PMID: 34520785 DOI: 10.1016/j.jhep.2021.08.030] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
29 Decraecker M, Dutartre D, Hiriart JB, Irles-Depé M, Chermak F, Foucher J, de Lédinghen V. Long-term prognosis of patients with metabolic (dysfunction)-associated fatty liver disease by non-invasive methods. Aliment Pharmacol Ther 2022. [PMID: 34978351 DOI: 10.1111/apt.16760] [Reference Citation Analysis]
30 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu., Clinical Practice Guideline Panel., Chair:., EASL Governing Board representative:., Panel members:. Reply to: Correspondence on "EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update". J Hepatol 2021:S0168-8278(21)02114-0. [PMID: 34742599 DOI: 10.1016/j.jhep.2021.10.008] [Reference Citation Analysis]
31 Reiberger T. The Value of Liver and Spleen Stiffness for Evaluation of Portal Hypertension in Compensated Cirrhosis. Hepatol Commun 2021. [PMID: 34904404 DOI: 10.1002/hep4.1855] [Reference Citation Analysis]
32 Vitellius C, Paisant A, Lannes A, Chaigneau J, Oberti F, Lebigot J, Fouchard I, Boursier J, David P, Aubé C, Calès P; CDMIR group. Liver fibrosis staging by computed tomography: Prospective randomized multicentric evaluation of image analyses. Clin Res Hepatol Gastroenterol 2021;46:101797. [PMID: 34500117 DOI: 10.1016/j.clinre.2021.101797] [Reference Citation Analysis]
33 De Broucker C, Plessier A, Ollivier-Hourmand I, Dharancy S, Bureau C, Cervoni JP, Sogni P, Goria O, Corcos O, Sartoris R, Ronot M, Vilgrain V, de Raucourt E, Zekrini K, Davy H, Durand F, Payancé A, Fidouh-Houhou N, Yazdanpanah Y, Valla D, Rautou PE. Multicenter study on recent portal venous system thrombosis associated with cytomegalovirus disease. J Hepatol 2021:S0168-8278(21)02041-9. [PMID: 34563580 DOI: 10.1016/j.jhep.2021.09.011] [Reference Citation Analysis]
34 Schattenberg JM, Anstee QM, Caussy C, Bugianesi E, Popovic B. Differences between current clinical guidelines for screening, diagnosis and management of nonalcoholic fatty liver disease and real-world practice: a targeted literature review. Expert Rev Gastroenterol Hepatol 2021;:1-14. [PMID: 34493137 DOI: 10.1080/17474124.2021.1974295] [Reference Citation Analysis]